GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MariMed Inc (XCNQ:MRMD) » Definitions » Cyclically Adjusted PS Ratio

MariMed (XCNQ:MRMD) Cyclically Adjusted PS Ratio : 1.21 (As of May. 17, 2024)


View and export this data going back to 2022. Start your Free Trial

What is MariMed Cyclically Adjusted PS Ratio?

As of today (2024-05-17), MariMed's current share price is C$0.34. MariMed's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was C$0.28. MariMed's Cyclically Adjusted PS Ratio for today is 1.21.

The historical rank and industry rank for MariMed's Cyclically Adjusted PS Ratio or its related term are showing as below:

XCNQ:MRMD' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.19   Med: 2.72   Max: 7.77
Current: 1.21

During the past years, MariMed's highest Cyclically Adjusted PS Ratio was 7.77. The lowest was 1.19. And the median was 2.72.

XCNQ:MRMD's Cyclically Adjusted PS Ratio is ranked better than
67.87% of 747 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs XCNQ:MRMD: 1.21

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

MariMed's adjusted revenue per share data for the three months ended in Mar. 2024 was C$0.137. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is C$0.28 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


MariMed Cyclically Adjusted PS Ratio Historical Data

The historical data trend for MariMed's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MariMed Cyclically Adjusted PS Ratio Chart

MariMed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 6.14 2.04 1.34

MariMed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.13 2.13 2.17 1.34 1.25

Competitive Comparison of MariMed's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MariMed's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MariMed's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where MariMed's Cyclically Adjusted PS Ratio falls into.



MariMed Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

MariMed's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.34/0.28
=1.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MariMed's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, MariMed's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.137/131.7762*131.7762
=0.137

Current CPI (Mar. 2024) = 131.7762.

MariMed Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.003 99.070 0.004
201503 0.004 99.621 0.005
201506 0.002 100.684 0.003
201509 0.016 100.392 0.021
201512 0.031 99.792 0.041
201603 0.025 100.470 0.033
201606 0.014 101.688 0.018
201609 0.018 101.861 0.023
201612 0.037 101.863 0.048
201703 0.024 102.862 0.031
201706 0.033 103.349 0.042
201709 0.013 104.136 0.016
201712 0.012 104.011 0.015
201803 0.015 105.290 0.019
201806 0.021 106.317 0.026
201809 0.023 106.507 0.028
201812 0.022 105.998 0.027
201903 0.022 107.251 0.027
201906 0.147 108.070 0.179
201909 0.068 108.329 0.083
201912 0.036 108.420 0.044
202003 0.045 108.902 0.054
202006 0.053 108.767 0.064
202009 0.051 109.815 0.061
202012 0.083 109.897 0.100
202103 0.091 111.754 0.107
202106 0.107 114.631 0.123
202109 0.111 115.734 0.126
202112 0.105 117.630 0.118
202203 0.105 121.301 0.114
202206 0.111 125.017 0.117
202209 0.119 125.227 0.125
202212 0.128 125.222 0.135
202303 0.137 127.348 0.142
202306 0.134 128.729 0.137
202309 0.141 129.860 0.143
202312 0.139 129.419 0.142
202403 0.137 131.776 0.137

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MariMed  (XCNQ:MRMD) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


MariMed Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of MariMed's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MariMed (XCNQ:MRMD) Business Description

Traded in Other Exchanges
Address
10 Oceana Way, Floor 2, Norwood, MA, USA, 02062
MariMed Inc is a multi-state operator in the United States cannabis industry. It develops, operates, manages, and optimizes regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult-use cannabis. MariMed also licenses its proprietary brands of cannabis products along with other top brands in domestic markets Sources of revenue are comprised of Product sales (retail and wholesale), Real estate rental income, Supply procurement, Management fees, and Licensing fees.
Executives
Jon R. Levine Senior Officer
Timothy Shaw Senior Officer